[go: up one dir, main page]

MX2013011336A - Composiciones farmaceuticas intranasales de benzodiazepina. - Google Patents

Composiciones farmaceuticas intranasales de benzodiazepina.

Info

Publication number
MX2013011336A
MX2013011336A MX2013011336A MX2013011336A MX2013011336A MX 2013011336 A MX2013011336 A MX 2013011336A MX 2013011336 A MX2013011336 A MX 2013011336A MX 2013011336 A MX2013011336 A MX 2013011336A MX 2013011336 A MX2013011336 A MX 2013011336A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
benzodiazepina
intranasal pharmaceutical
intranasal
benzodiazepine
Prior art date
Application number
MX2013011336A
Other languages
English (en)
Other versions
MX357800B (es
Inventor
Moise A Khayrallah
Myoung-Ki Baek
Jae-Hoon Jo
Hye-Jin Chang
Gary Bream
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of MX2013011336A publication Critical patent/MX2013011336A/es
Publication of MX357800B publication Critical patent/MX357800B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere generalmente a composiciones farmacéuticas intranasales que comprenden una benzodiazepina y métodos de uso de las mismas, que pueden proveer un efecto terapéutico sin una disminución en la presión sanguínea y/o el pulso después de la administración de la composición farmacéutica.
MX2013011336A 2011-03-31 2012-03-30 Composiciones farmacéuticas intranasales de benzodiazepina. MX357800B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161469940P 2011-03-31 2011-03-31
PCT/US2012/031453 WO2012135619A2 (en) 2011-03-31 2012-03-30 Intranasal benzodiazepine pharmaceutical compositions

Publications (2)

Publication Number Publication Date
MX2013011336A true MX2013011336A (es) 2013-12-16
MX357800B MX357800B (es) 2018-07-25

Family

ID=46928023

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011336A MX357800B (es) 2011-03-31 2012-03-30 Composiciones farmacéuticas intranasales de benzodiazepina.

Country Status (15)

Country Link
US (3) US20120252793A1 (es)
EP (1) EP2691100A4 (es)
JP (1) JP2014509655A (es)
KR (1) KR20140029426A (es)
CN (1) CN103619338B (es)
AR (1) AR085927A1 (es)
AU (1) AU2012236334B2 (es)
BR (1) BR112013024968A2 (es)
CA (1) CA2831308A1 (es)
MX (1) MX357800B (es)
PH (2) PH12013501915A1 (es)
RU (2) RU2013148120A (es)
SG (2) SG193958A1 (es)
TW (1) TWI601532B (es)
WO (1) WO2012135619A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
JP5929800B2 (ja) * 2012-04-03 2016-06-08 コニカミノルタ株式会社 定着液および画像形成方法
WO2018222922A1 (en) * 2017-06-02 2018-12-06 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US11534493B2 (en) * 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
AU2019205329B2 (en) 2018-01-05 2023-04-20 Impel Pharmaceuticals Inc. Intranasal delivery of olanzapine by precision olfactory device
WO2019182745A1 (en) * 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
CN112384199A (zh) 2018-06-04 2021-02-19 阿尔库缇斯股份有限公司 改善罗氟司特皮肤渗透滞后时间的方法和制剂
CN111529489A (zh) * 2020-04-17 2020-08-14 山东省药学科学院 一种含有地西泮的鼻腔喷雾剂
AU2021393513A1 (en) 2020-12-04 2023-07-06 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having antifungal properties
US12453721B2 (en) 2021-12-28 2025-10-28 Arcutis Biotherapeutics, Inc. Topical roflumilast aerosol foams
JP2025530005A (ja) 2022-09-15 2025-09-09 アーキュティス・バイオセラピューティクス・インコーポレーテッド ロフルミラスト及び大量のロフルミラストを溶解可能な溶媒の医薬組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE229817T1 (de) * 1996-10-24 2003-01-15 Alza Corp Penetrationsfördernde substanzen für die transdermale verabreichung von wirkstoffen, vorrichtungen und verfahren zur herstellung
EP1196156B1 (en) * 1999-07-26 2008-04-30 SK Holdings Co., Ltd. Transnasal anticonvulsive compositions
DK1539285T4 (da) * 2002-09-03 2012-01-02 Pharmacure Health Care Ab Næsesprayer
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
US7745430B2 (en) * 2006-11-15 2010-06-29 Sk Holdings Co., Ltd. Transnasal anticonvulsive pharmaceutical composition
US8946208B2 (en) * 2007-08-31 2015-02-03 Archimedes Development Limited Non-aqueous pharmaceutical composition
KR101517415B1 (ko) * 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
US8242141B2 (en) * 2009-09-16 2012-08-14 Allergan, Inc. Compositions and methods for treating seizure disorders

Also Published As

Publication number Publication date
WO2012135619A3 (en) 2012-11-22
SG193958A1 (en) 2013-11-29
EP2691100A4 (en) 2014-09-24
TW201302204A (zh) 2013-01-16
SG10201602176RA (en) 2016-04-28
CN103619338A (zh) 2014-03-05
PH12017501688A1 (en) 2018-09-10
RU2018135967A (ru) 2018-11-14
WO2012135619A2 (en) 2012-10-04
AU2012236334A1 (en) 2013-10-10
MX357800B (es) 2018-07-25
PH12013501915A1 (en) 2019-11-29
KR20140029426A (ko) 2014-03-10
US20170151258A1 (en) 2017-06-01
RU2013148120A (ru) 2015-05-10
TWI601532B (zh) 2017-10-11
CN103619338B (zh) 2016-06-22
CA2831308A1 (en) 2012-10-04
EP2691100A2 (en) 2014-02-05
US20140128381A1 (en) 2014-05-08
BR112013024968A2 (pt) 2016-12-20
AR085927A1 (es) 2013-11-06
US20120252793A1 (en) 2012-10-04
JP2014509655A (ja) 2014-04-21
AU2012236334B2 (en) 2017-02-16
HK1195252A1 (zh) 2014-11-07

Similar Documents

Publication Publication Date Title
MX2013011336A (es) Composiciones farmaceuticas intranasales de benzodiazepina.
GT201400009A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk
EA201400986A1 (ru) Фармацевтические композиции, содержащие метформин и ингибитор dpp-4 или ингибитор sglt-2
EA201200550A1 (ru) Фармацевтические композиции, включающие bi-1356 и метформин
CR20110424A (es) Derivados de aminotetralina, composiciones farmacéuticas que los contienen, y sus usos en terapia
CR20140318A (es) Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
MX2015009105A (es) Composiciones en solucion solida y su uso en inflamacion cronica.
MX353827B (es) Formas de rifaximina y usos de la misma.
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
UY35210A (es) Inhibidores de autotaxina
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
CL2014001704A1 (es) Derivados de amida ciclica como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa; composicion farmaceutica que los comprende y el uso de los mismos en la prevencion o tratamiento de enfermedades tales como la diabetes.
MX340983B (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
ES2524385R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
CO6920289A2 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib.
AR082215A1 (es) Composicion farmaceutica agradable al paladar
EA201400444A1 (ru) Производные 2-оксопиперидинила
SV2010003773A (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
UA105944C2 (uk) Комбінація теоброміну з деконгестантом і її застосування для лікування кашлю
UY33789A (es) Combinación que comprende un derivado de la familia de las combretastatinas y cetuximab

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: SK BIOPHARMACEUTICALS CO., LTD.